You should consider shares of CRISPR Therapeutics AG (NASDAQ:CRSP) and CannTrust Holdings Inc. (NYSE:CTST) if you are looking for a great stocks to invest in. Starting with the CRSP shares, which traded at $71.65 at the close of the recent session, gaining 5.20%. On Friday, the company’s shares shed $3.54 from its value which represented in intraday trading. The stock is now 90.46% higher in year-to-date (YTD) trading. CRSP’s intraday high was $72.1164 while its lowest price touched $68.00. The stock’s 52-week high price is $74.00, which means the current price is at -3.18%. In terms of trading activity, the daily trading volume rose to 1012935 against 200-day average trading volume of 678,833 shares.
What are analyst forecasts for CRISPR Therapeutics AG (NASDAQ:CRSP)?
At a consensus rating of 4.25, CRSP is trending as a streaking Moderate Buy, as it has been the case a month ago when 12 analysts called it a Moderate Buy. Two months ago, 14 analysts recommended, on average, that CRSP stock is a Moderate Buy. The Healthcare company’s shares’ overall bullish trend saw it close lower on Friday compared to its opening price of $68.19 on the day.
Forecasts for CRISPR Therapeutics AG (NASDAQ:CRSP) give the stock a fair value for the growth of 10.44% from its last price. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $80.00, which means the price per share could rise by nearly $8.35. The price range target is between a low of $28.00 and a high of $104.00. The stock would need to gain by about $31.11 to hit the estimated high or 0.31% from its 12-month low.
The consensus among 16 analysts is that it is a good time for one to Overweight in the CRISPR Therapeutics AG. 12 analysts rate CRSP as a Buy, with 2 of 16 analysts rate it as a Sell. 0 have valued the stock as Overweight and 2 have recommended that investors Hold.
CRISPR Therapeutics AG (NASDAQ:CRSP) Upgrades and Downgrades
In terms of rating changes, William Blair on November 19, 2019, Upgrade CRISPR Therapeutics AG (CRSP) at Outperform. Analysts at Oppenheimer have assigned a Outperform rating for the stock in their research note on November 12, 2019 with an estimated price target of $65. Moreover, Jefferies analysts issued a rating of Buy for the stock on August 01, 2019, giving it a price target of $64 for the next 12 months. On July 26, 2019, the stock earned a Buy rating due to an analyst call from Canaccord Genuity, while analysts from ROTH Capital on June 10, 2019 suggested that the stock is Buy.
CannTrust Holdings Inc. (NYSE:CTST) adds -$0.03 on Friday
The CTST stock has tanked -83.45% year-to-date and is currently trading at $0.80, which is -92.15% below its 52-week high. The company shares lost -3.67% on the day and have risen nearly 3.22% off a low hit. As of 11/29/19, this stock has fallen -16.56% during the week and closed at $0.83 in the previous session. However, recent CannTrust Holdings Inc. stock performance shows that CTST shares are -26.76% down over the last month, and -54.14% down for the last three months.
Who owns shares in CannTrust Holdings Inc. (CTST)?
ETF Managers Group, LLC tops the list of institutional owners as it is holding 18.88 million shares or 13.35% of shares outstanding. Manufacturers Life Insurance Co. and Morgan Stanley held 10.14 million and 1.24 million representing 7.17% and 0.87% respectively at the close of the last trading session. As of Sep 29, 2019, Goldman Sachs Group, Inc. accounted for 504623.0 shares at over 565177.0. This represented 0.36% of shares outstanding. Two Sigma Investments, LP held 352321.0 shares at over 394599.0 representing 0.25% of shares outstanding.